Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
This article is commented on by the following:
Abstract
Purpose:
We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezūm™) for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia.
Materials and Methods:
A total of 197 subjects
Results:
Significant improvement of lower urinary tract symptoms was observed at
Conclusions:
Minimally invasive treatment with water vapor thermal therapy provides significant and durable symptom relief as well as flow rate improvements through 5 years, with low surgical re-treatment rates and without impacting sexual function. It is a versatile therapy, providing successful treatment to obstructive lateral and middle lobes.
References
- 1. : The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am 2016; 43: 289. Google Scholar
- 2. : Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline amendment 2019. J Urol 2019; 202: 592. Link, Google Scholar
- 3. : BPH: why do patients fail medical therapy?Curr Urol Rep 2019; 20: 40. Google Scholar
- 4. : EAU guidelines on management of non-neurogenic male LUTS. Presented at 2020 EAU Annual Congress, Amsterdam, Arnhem, The Netherlands. Available at http://uroweb.org/guidelines/compilations-of-all-guidelines/. Google Scholar
- 5. : The adjustable transobturator male system in stress urinary incontinence after transurethral resection of the prostate. Urology 2017; 109: 184. Google Scholar
- 6. Boston Scientific Corporation: Intended use. In: Rezum Instruction for Use, 10-2019 p. 5. Google Scholar
- 7. : Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum(R) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 2015; 7: 13. Google Scholar
- 8. : Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol 2006; 6: 14. Google Scholar
- 9. : Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia?J Sex Med 2018; 15: 1728. Google Scholar
- 10. National Institute for Health and Care Excellence: Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (24 June 2020). NICE Guideline No. MTG49. Available at https://www.nice.org.uk/guidance/mtg49. Google Scholar
- 11. : EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Arnhem, The Netherlands: EAU Guidelines Office 2020. Available at http://uroweb.org/guidelines/compilations-of-all-guidelines/. Google Scholar
- 12. : Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 2019; 126: 171. Google Scholar
- 13. : Three-year outcomes of the prospective, randomized controlled Rezum System Study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology 2018; 111: 1. Google Scholar
- 14. : Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 2017; 197: 1507. Link, Google Scholar
- 15. : Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2016; 195: 1529. Link, Google Scholar
- 16. : Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol 2014; 191: 1828. Link, Google Scholar
- 17. : Prostatic urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift study. Prostate Cancer Prostatic Dis 2019; 22: 411. Google Scholar
- 18. U.S. Food and Drug Administration: Select Updates for Guidance for the Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH): Draft Guidance for Industry and Food and Drug Administration Staff (July 14, 2020). Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/select-updates-guidance-non-clinical-and-clinical-investigation-devices-used-treatment-benign. Google Scholar
- 19. : Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. J Urol 2012; 187: 1732. Link, Google Scholar
- 20. : Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017; 24: 8802. Medline, Google Scholar
- 21. : Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003; 44: 89. Google Scholar
- 22. : Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails. J Urol 2007; 177: 1047. Link, Google Scholar
- 23. : Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004; 171: 2336. Link, Google Scholar
- 24. : Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol 200; 405: 2018. Google Scholar
- 25. : Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep 2018; 19: 72. Google Scholar
- 26. : Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2,000 patients. J Urol 2020; 204: 1019. Link, Google Scholar
- 27. : Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 2006; 50: 969. Google Scholar
- 28. : Long-term clinical efficacy and safety profile of transurethral resection of prostate versus plasmakinetic resection of the prostate for benign prostatic hyperplasia. Urology 2017; 103: 198. Google Scholar
- 29. : Potassium-titanyl-phosphate laser photoselective vaporization for benign prostatic hyperplasia: 5-year follow-up from a district general hospital. J Endourol 2012; 26: 878. Google Scholar
- 30. : Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. J Urol 2011; 185: 1804. Link, Google Scholar
Funding for this study was provided by Boston Scientific.